Recruiting
Phase 2

Atorvastatin

Sponsor:

Johns Hopkins University

Code:

NCT04765137

Conditions

Mild Cognitive Impairment

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Interventions

Atorvastatin Oral Tablet

Study Details

Brief summary:

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Conditions

Mild Cognitive Impairment

Study ID

NCT04765137

Start date

May 21, 2021

Status verified date

Jul, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Jul 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria are chosen to include participants with MCI, enriched for vascular risk factors:

  • MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
  • Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.
  • Not demented by history.
  • Not taking statins currently or in the last 6 months.
  • Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion Criteria:

  • Taking a statin currently or have taken a statin in the last 6 months.
  • Contraindications to taking a statin.
  • Transplant patient taking cyclosporine.
  • Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
  • Diagnosis of dementia by history.
  • Current diagnosis of substance abuse.
  • History of stroke or myocardial infarction in past 6 months.
  • History of HIV.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Atorvastatin 40 mg

Participants receive 40 mg atorvastatin orally daily in the evening.

Interventions

Atorvastatin Oral Tablet

Atorvastatin pill 40 mg to be taken every night

Primary outcome measure

  • Change of MRI whole brain cerebrovascular reactivity (wbCVR) [ Time Frame: Baseline and 12 weeks ]

Central Contacts and Locations

Central contacts

Samantha Horn

410-550-9020shorn8@jhmi.edu

Ritu Agarwal

410-550-9020ragarw19@jhmi.edu

Locations

Johns Hopkins University, Bayview Medical Center

Recruiting

Baltimore, Maryland, United States, 21224

Contacts

Samantha Horn

410-550-9020shorn8@jhmi.edu

Ritu Agarwal

410-550-9020ragarw19@jhmi.edu

Principal Investigator:

Paul Rosenberg, MD

More Information

Sponsor

Johns Hopkins University

Last update posted

Jul 13, 2026

Last verified

Jul, 2026

Keywords

  • Cerebral Vascular Reactivity

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2026-07-13.